Study of Coenzyme Q10 Treatment in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease

What this Trial Is About

Metabolic-dysfunction associated fatty liver disease MAFLD is a common liver condition linked to factors like ethnicity, genetics, metabolism, and the environment. It is increasingly prevalent worldwide and is especially common among people with type 2 diabetes. This study investigates whether high doses of coenzyme Q10, known for its antioxidant and anti-inflammatory properties, can improve inflammation and liver-related biochemical markers in patients with MAFLD. Participants in this study will be randomly assigned to one of two groups. One group will receive standard care, which includes lifestyle changes such as diet, weight loss, and physical activity. The other group will receive the standard care plus Coenzyme Q10 Forte400 mg daily 100 mg twice a day for twelve weeks. This dose is higher than in previous studies and aims to better evaluate the effects of CoQ10 on liver health in MAFLD patients. During the study, participants will undergo assessments of liver steatosis using imaging at the start and after 12 weeks. Blood tests will measure inflammatory markers like tumor necrosis factor-alpha, liver enzymes, kidney function, and other biochemical indicators. Quality of life will also be assessed. The study will monitor changes from baseline to 12 weeks to understand the tolerability and effects of CoQ10 in this population, with total participation lasting about three months.

Effect of CoQ10 on the Outcome of MAFLD Patients